MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...

Ueda is holding an expandable toy that he uses to demonstrate how the company’s computationally designed Antibody Cages work. (GeekWire Photo / Alan Boyle) Three weeks after University of ...

Tegoprubart, manufactured by Eledon Pharmaceuticals, Inc., is an investigational anti-CD40L monoclonal antibody, meaning it is made in a lab, and works by tricking the immune system to recognize ...